Quick Answer
UNITED THERAPEUTICS Corp reported Revenue From Contract With Customer Excluding Assessed Tax of $3.18 billion for the year ending 2025.
- UNITED THERAPEUTICS Corp showed an increase of +10.6% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from UNITED THERAPEUTICS Corp's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $370.50 million | Q2 2017: $444.60 million | Q3 2017: $445.50 million | Q1 2018: $389.20 million | Q2 2018: $444.50 million | Q3 2018: $412.70 million | Q1 2019: $362.60 million | Q2 2019: $373.60 million | Q3 2019: $401.50 million | Q1 2020: $356.30 million | Q2 2020: $362.00 million | Q3 2020: $380.10 million | Q1 2021: $379.10 million | Q2 2021: $446.50 million | Q3 2021: $444.70 million | Q1 2022: $461.90 million | Q2 2022: $466.90 million | Q3 2022: $516.00 million | Q1 2023: $506.90 million | Q2 2023: $596.50 million | Q3 2023: $609.40 million | Q1 2024: $677.70 million | Q2 2024: $714.90 million | Q3 2024: $748.90 million | Q1 2025: $794.40 million | Q2 2025: $798.60 million | Q3 2025: $799.50 million.
- Over the full 10 years of available data (2016 to 2025), UNITED THERAPEUTICS Corp's Revenue From Contract With Customer Excluding Assessed Tax has grown by 99.1%.
- Historical annual values: Fiscal year 2025: $3.18 billion | Fiscal year 2024: $2.88 billion | Fiscal year 2023: $2.33 billion | Fiscal year 2022: $1.94 billion | Fiscal year 2021: $1.69 billion | Fiscal year 2020: $1.48 billion | Fiscal year 2019: $1.45 billion | Fiscal year 2018: $1.63 billion | Fiscal year 2017: $1.73 billion | Fiscal year 2016: $1.60 billion.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: